IP Library Granted Patent US 8,309,601
Granted Patent B2
US 8,309,601 · App. 13/306,043 · Granted Nov 13, 2012

Forms of CDDO methyl ester

Assignee: Reata Pharmaceuticals, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,309,601
App. No.
13/306,043
Granted
Nov 13, 2012
Kind
B2
Abstract

A triterpenoid compound, methyl 2-cyano-3,12-dioxoleana-1,9(11)-dien-28-oate (CDDO methyl ester), has a non-crystalline, glassy solid form and a non-hydrous crystalline form that can prepared, for example, from a saturated methanol solution. The glassy form displays an enhanced bioavailability over the non-hydrous crystalline form. Each form of CDDO methyl ester is a superior candidate for use, typically in solid dosage form, for treating a variety of disease states, generally associated with inflammation.

Claims (9)

1. Anhydrous, crystalline methyl 2-cyano-3,12-dioxoleana-1,9(11)-dien-28-oate (CDDO-methyl ester) characterized in that its X-ray powder diffractogram comprises peaks at 8.78° 2θ, 12.94° 2θ, 13.35° 2θ, 14.18° 2θ, and 17.4° 2θ±0.2° 2θ based upon data collected on a diffractometer with Cu K α radiation.

2. The CDDO-methyl ester according to claim 1 , wherein the X-ray powder diffractogram is substantially as shown in FIG. 18 .

3. The CDDO-methyl ester according to claim 1 , further characterized in that its differential scanning calorimetry curve comprises a baseline shift at approximately 157° C. and an endotherm maximum at about 224° C.

4. The CDDO-methyl ester according to claim 3 , wherein the differential scanning calorimetry curve is substantially as shown in FIG. 3 .

5. A pharmaceutical composition comprising a therapeutically effective amount of the CDDO-methyl ester according to claim 1 and one or more solid pharmaceutically acceptable carriers.

6. The pharmaceutical composition according to claim 5 , wherein the CDDO-methyl ester is micronized and the solid pharmaceutically acceptable carriers are edible carriers.

7. A method for treating a chronic inflammatory condition in a subject suffering therefrom, comprising administering to the subject a therapeutically effective amount of CDDO-methyl ester according to claim 1 .

8. Crystalline CDDO-methyl ester hemibenzenate, characterized in that its X-ray powder diffractogram comprises peaks at 9.25° 2θ, 14.17° 2θ, , 14.62° 2θ, 16.32°2θ, and 17.11° 2θ±0.2° 2θ based upon data collected on a diffractometer with Cu K α radiation.

9. The crystalline CDDO-methyl ester hemibenzenate according to claim 8 , further characterized in that it has a differential scanning calorimetry curve as substantially shown in FIG. 23 .

Assignments (8)
RELEASE OF SECURITY INTEREST Recorded Apr 9, 2025
From: BIOPHARMA CREDIT PLC
To: REATA PHARMACEUTICALS HOLDINGS, LLC; REATA PHARMACEUTICALS GLOBAL, INC.; REATA PHARMACEUTICALS, INC.
Reel/Frame 070793/0228 →
RELEASE OF SECURITY INTEREST Recorded Apr 9, 2025
From: BIOPHARMA CREDIT PLC
To: REATA PHARMACEUTICALS HOLDINGS, LLC; REATA PHARMACEUTICALS GLOBAL, INC.; REATA PHARMACEUTICALS, INC.
Reel/Frame 070793/0130 →
AMENDED AND RESTATED PATENT SECURITY AGREEMENT Recorded Jul 12, 2023
From: REATA PHARMACEUTICALS HOLDINGS, LLC; REATA PHARMACEUTICALS GLOBAL, INC.; REATA PHARMACEUTICALS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 064264/0557 →
PATENT SECURITY AGREEMENT Recorded May 18, 2023
From: REATA PHARMACEUTICALS HOLDINGS, LLC; REATA PHARMACEUTICALS GLOBAL, INC.; REATA PHARMACEUTICALS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 063697/0461 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 3, 2021
From: REATA PHARMACEUTICALS, INC.
To: REATA PHARMACEUTICALS HOLDINGS, LLC
Reel/Frame 058301/0262 →
RELEASE OF SECURITY INTEREST Recorded Jun 24, 2020
From: OXFORD FINANCE LLC, AS COLLATERAL AGENT
To: REATA PHARMACEUTICALS, INC.
Reel/Frame 053034/0018 →
SECURITY INTEREST Recorded Jun 14, 2018
From: REATA PHARMACEUTICALS, INC.
To: OXFORD FINANCE LLC, AS COLLATERAL AGENT
Reel/Frame 046357/0605 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 29, 2011
From: WALLING, JOHN; PARENT, STEPHEN D.; JONAITIS, DAVID T.; KRAL, ROBERT M., JR.
To: REATA PHARMACEUTICALS, INC.
Reel/Frame 027292/0007 →
Continuity (3)
Continuation 12191176 · Aug 13, 2008
Provisional Application 60955939 · Aug 15, 2007
Related Publication 20120071684A1 · Mar 22, 2012